Effects of desmopressin (DDAVP) on memory impairment following electroconvulsive therapy (ECT)

Abdollahian, Ebrahim; Sargolzaee, Mohammad Reza; Hajzade, Moosareza; Mohebbi, Mohammad D.; Javanbakht, Arash

doi:10.1111/j.0924-2708.2004.00064.x

Cited by 3 publications

(1 citation statement)

References 12 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various strategies have been adopted to decrease those adverse complications, some non-pharmacological of which include changing electrode placement, using ultra-brief (and brief) pulse waves to induce seizures, and reducing stimulation intensity (3). Moreover, pharmacological agents have also been used to alleviate ECT-induced cognitive impairments, some of which encompass adjunctive treatment with dexamethasone (4), vasopressin (5,6), thyroid hormones (7), naloxone (8), calcium channel blockers (9), some medicinal plants (10), and memantine (11,12) during ECT.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of Donepezil in Improving Cognitive Impairment Induced by Electroconvulsive Therapy in Patients with Mood Disorders: A Randomized, Double-blind, Placebo-Controlled Trial

Zarean

Sedehi

Heshmati

2021

Iran J Psychiatry Behav Sci

View full text Add to dashboard Cite

Background: Electroconvulsive therapy (ECT) is an effective strategy in the treatment of mood disorders; however, it is associated with some cognitive complications. Objectives: This study aimed to evaluate the efficacy of donepezil as an acetylcholinesterase inhibitor in improving cognitive impairment induced by ECT in mood disorder patients. Methods: Ninety-six mood disorder patients were randomly assigned to the donepezil (5mg/day) or placebo groups. The Persian versions of the Mini-Mental Status examination (MMSE) and Addenbrooke’s Cognitive Examination Revised (ACE-R) were used to evaluate cognitive performance before the first ECT session, after the fourth ECT session, and four weeks after the last ECT session. Results: The mean scores of MMSE and ACE-R revealed significant improvement in the donepezil group over time (P < 0.001). All ACE-R subscales increased significantly following the intervention implementation in the donepezil group (P < 0.001). Furthermore, the donepezil group reported no remarkable complications and completed the study. Conclusions: Donepezil co-administration with ECT may improve the ECT-induced cognitive disturbances.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of Donepezil in Improving Cognitive Impairment Induced by Electroconvulsive Therapy in Patients with Mood Disorders: A Randomized, Double-blind, Placebo-Controlled Trial

Zarean

Sedehi

Heshmati

2021

Iran J Psychiatry Behav Sci

View full text Add to dashboard Cite

show abstract

The effects of aromatherapy with clove essential oil on memory function of patients during electroconvulsive therapy: A randomized controlled trial

Ansariniaki

Behnam

Keyghobady

et al. 2022

European Journal of Integrative Medicine

View full text Add to dashboard Cite

Potential clinical applications of current and future oral forms of desmopressin (Review)

Everaert,

Holm‑larsen,

Bou Kheir

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Desmopressin is a synthetic analogue of vasopressin and a selective vasopressin receptor 2 agonist. It was first synthesised in 1967 and utilised for its antidiuretic properties. It is also used in bleeding disorders to enhance clotting. Other potential uses of the drug have been reported. The present review aims to provide a broad overview of the literature on potential further uses of oral forms of desmopressin. Key therapeutic areas of interest were identified based on known physiological activities/targets of desmopressin or reports of an effect of desmopressin in the literature. The feasibility of adequate dosing with oral forms of the drug was also considered. Systematic literature searches were carried out using the silvi.ai software for the identified areas, and summaries of available papers were included in tables and discussed. The results of the searches showed that desmopressin has been investigated for its efficacy in a number of areas, including bleeding control, renal colic, the central nervous system and oncology. Evidence suggests that oral desmopressin may have the potential to be of clinical benefit for renal colic and bleeding control in particular. However, further research is needed to clarify its effect in these areas, including randomised controlled studies and studies specifically of oral formulations (and doses). Further research may also yield findings for cancer, cognition and overactive bladder. Contents 1. Introduction 2. Methods 3. Results of literature review and discussion of findings 4. Conclusion

show abstract

Effects of desmopressin (DDAVP) on memory impairment following electroconvulsive therapy (ECT)

Abstract: This study confirms the protective effect of desmopressin against memory impairment. The results confirm that memory impairment is a common side-effect of ECT and suggest that desmopressin may prevent ECT-induced memory impairment by its effects on memory and the learning process.

Cited by 3 publications

References 12 publications

Efficacy of Donepezil in Improving Cognitive Impairment Induced by Electroconvulsive Therapy in Patients with Mood Disorders: A Randomized, Double-blind, Placebo-Controlled Trial

Efficacy of Donepezil in Improving Cognitive Impairment Induced by Electroconvulsive Therapy in Patients with Mood Disorders: A Randomized, Double-blind, Placebo-Controlled Trial

The effects of aromatherapy with clove essential oil on memory function of patients during electroconvulsive therapy: A randomized controlled trial

Potential clinical applications of current and future oral forms of desmopressin (Review)

Contact Info

Product

Resources

About